These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 28186357)

  • 1. Short- and long-term outcomes with renin-angiotensin-aldosterone inhibitors in renal transplant recipients: A meta-analysis of randomized controlled trials.
    Liao RX; Lyu XF; Tang WJ; Gao K
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28186357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
    Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
    Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adding Rheum officinale to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal function in patients with chronic renal failure: A meta-analysis of randomized controlled trials
.
    Yang Y; Ma YP; Zhang Z; Dai PL; Li P; Li WG
    Clin Nephrol; 2018 Jun; 89(6):445-454. PubMed ID: 29208203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of renin-angiotensin system inhibitors on survival in kidney transplant recipients: A systematic review and meta-analysis.
    Jiang YM; Song TR; Qiu Y; Liu JP; Wang XD; Huang ZL; Lin T
    Kaohsiung J Med Sci; 2018 Jan; 34(1):1-13. PubMed ID: 29310811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y; Ma X; Zheng J; Jia J; Yan T
    BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
    Zhang L; Zeng X; Fu P; Wu HM
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
    MacKinnon M; Shurraw S; Akbari A; Knoll GA; Jaffey J; Clark HD
    Am J Kidney Dis; 2006 Jul; 48(1):8-20. PubMed ID: 16797382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials.
    Hiremath S; Fergusson DA; Fergusson N; Bennett A; Knoll GA
    Am J Kidney Dis; 2017 Jan; 69(1):78-86. PubMed ID: 27712852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
    Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J
    Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on left ventricular mass index and ejection fraction in hemodialysis patients: A meta-analysis with trial sequential analysis of randomized controlled trials.
    Yang Y; Wang R; Li MX; Xing Y; Li WG
    Int J Cardiol; 2016 Sep; 219():350-7. PubMed ID: 27352206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.